{"cik":"0001785530","ticker":"HOWL","name":"Werewolf Therapeutics, Inc.","sic_code":"2834","sic_description":"Pharmaceutical Preparations","exchange":"Nasdaq","state_of_incorporation":"DE","fiscal_year_end":"1231","first_filing_date":"2026-05-12","last_filing_date":"2026-07-08","url":"/sec/cik-0001785530","insider_summary":{"total_transactions":97,"unique_insiders":5,"latest_transaction":"2026-07-07"},"recent_filings":[{"accession_number":"0001346824-26-000185","form_type":"SCHEDULE 13D/A","form_type_family":"other","doc_date":"2026-06-26","title":"SCHEDULE 13D/A — RA CAPITAL MANAGEMENT, L.P. — 2026-06-26","url_slug":"/sec/cik-0001346824/schedule-13d-a/0001346824-26-000185","edgar_url":"https://www.sec.gov/Archives/edgar/data/1785530/0001346824-26-000185-index.html"},{"accession_number":"0001628280-26-036035","form_type":"144","form_type_family":"other","doc_date":"2026-05-18","title":"144 — UBS Oncology Impact Fund L.P. — 2026-05-18","url_slug":"/sec/cik-0001691428/144/0001628280-26-036035","edgar_url":"https://www.sec.gov/Archives/edgar/data/1785530/0001628280-26-036035-index.html"}],"related_endpoints":{"profile":"/sec/HOWL/profile","timeline":"/sec/HOWL/timeline","peers":"/sec/HOWL/peers","insider_pulse":"/sec/HOWL/insider-pulse","insider_summary":"/sec/HOWL/insider-summary","insider_transactions":"/sec/HOWL/insider-transactions","form144":"/sec/HOWL/form144","holdings_as_filer":"/sec/HOWL/holdings","financial_facts":"/sec/HOWL/financial-facts","derivatives":"/sec/HOWL/derivatives","officers":"/sec/HOWL/officers","insider_network":"/sec/HOWL/insider-network","risk_flags":"/sec/HOWL/risk-flags","filings":"/sec/HOWL/filings","cross_topic_dossier":"/api/v1/dossier?ticker=HOWL"}}